Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- (3?,12?,20R)-12,20-dihydroxydammar-24-en-3-yl O-?-D-xylopyranosyl-(1?2)-O-?-D-glucopyranosyl-(1?2)-?-D-glucopyranoside
- Correlated keywords
- ft-1 panax HIF1? SHSY5Y LNAME COL-1a1 3a1 TGF?1 TGF?3 PI3-K
- Product Overview:
Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities.{37598,37599,37600,37601,37602} It induces proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) via nuclear translocation of hypoxia-inducible factor-1? (HIF-1?) and activation of the PI3K/AKT and Raf/MEK/ERK signaling pathways in a manner dependent on mammalian target of rapamycin (mTOR).{37598} Notoginsenoside Ft1 (45 ?M) induces cell cycle arrest at the S and G2/M phases and promotes apoptosis of SH-SY5Y cells.{37599} It increases cGMP levels and induces relaxation of isolated precontracted rat mesenteric arteries, effects that are reversed by the nitric oxide synthase inhibitor L-NAME (Item No. 80210) and ODQ (Item No. 81410), an inhibitor of soluble guanylyl cyclase.{37600} In vivo, notoginsenoside Ft1 (0.25, 2.5, and 25 mg/kg) promotes angiogenesis and decreases wound diameter in a mouse model of punched-hole ear injury.{37598} Notoginsenoside Ft1 (1.25 mg/kg) decreases tail bleeding time and increases thrombus weight in a rat tail bleeding assay.{37601} Topical administration of notoginsenoside Ft1 increases mRNA expression of the collagen expression, fibroblast proliferation, and scar formation genes COL1A1, COL3A1, TGF-?1, TGF-?3, and fibronectin, promotes neovascularization, reduces monocyte infiltration, and shortens wound closure time in a db/db mouse model of diabetic foot ulcers.{37602}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.